An atlas of active enhancers across human cell types and tissuesRobin Andersson, Albin Sandelin, Claudia Gebhard et al.|Nature|2014Cited by 2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Brian Angus et al.|The Lancet|2020Cited by 2.6k
A minimal common outcome measure set for COVID-19 clinical researchJohn C. Marshall, Halima Salisu-Kabara, Thomas Glueck et al.|The Lancet Infectious Diseases|2020Cited by 1.8k
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Yanchun Peng, Philip Goulder, Alexander J. Mentzer et al.|Nature Immunology|2020Cited by 1.4k
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Malcolm G. Semple, Jiandong Huo et al.|Cell|2022Cited by 1k